Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Natl Compr Canc Netw ; 17(8): 911-920, 2019 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-31390590

RESUMEN

BACKGROUND: This study evaluated the effectiveness of a screening and stepped care program (the TES program) in reducing psychological distress compared with care as usual (CAU) in patients with metastatic colorectal cancer starting with first-line systemic palliative treatment. PATIENTS AND METHODS: In this cluster randomized trial, 16 hospitals were assigned to the TES program or CAU. Patients in the TES arm were screened for psychological distress with the Hospital Anxiety and Depression Scale and the Distress Thermometer/Problem List (at baseline and 10 and 18 weeks). Stepped care was offered to patients with distress or expressed needs, and it consisted of watchful waiting, guided self-help, face-to-face problem-solving therapy, or referral to specialized mental healthcare. The primary outcome was change in psychological distress over time, and secondary outcomes were quality of life, satisfaction with care, and recognition and referral of distressed patients by clinicians. Linear mixed models and effect sizes were used to evaluate differences. RESULTS: A total of 349 patients were randomized; 184 received the TES program and 165 received CAU. In the TES arm, 60.3% of the patients screened positive for psychological distress, 26.1% of which entered the stepped care program (14.7% used only watchful waiting and 11.4% used at least one of the other treatment steps). The observed low use of the TES program led us to pursue a futility analysis, which showed a small conditional power and therefore resulted in halted recruitment for this study. No difference was seen in change in psychological distress over time between the 2 groups (effect size, -0.16; 95% CI, -0.35 to 0.03; P>.05). The TES group reported higher satisfaction with the received treatment and better cognitive quality of life (all P<.05). CONCLUSIONS: As a result of the low use of stepped care, a combined screening and treatment program targeting psychological distress in patients with metastatic colorectal cancer did not improve psychological distress. Our results suggest that enhanced evaluation of psychosocial concerns may improve aspects of patient well-being.


Asunto(s)
Neoplasias Colorrectales/complicaciones , Distrés Psicológico , Estrés Psicológico , Trastornos Relacionados con Traumatismos y Factores de Estrés/etiología , Trastornos Relacionados con Traumatismos y Factores de Estrés/terapia , Anciano , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/terapia , Manejo de la Enfermedad , Femenino , Humanos , Masculino , Inutilidad Médica , Persona de Mediana Edad , Metástasis de la Neoplasia , Estadificación de Neoplasias , Países Bajos/epidemiología , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Trastornos Relacionados con Traumatismos y Factores de Estrés/diagnóstico , Trastornos Relacionados con Traumatismos y Factores de Estrés/epidemiología
2.
J Pain Symptom Manage ; 52(4): 560-569.e1, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27650011

RESUMEN

CONTEXT: Studies indicate adverse effects of breast cancer (BC) and cancer treatment on cognitive function. OBJECTIVES: To investigate the effects of systemic treatment on cognitive performance in BC patients. METHODS: Participants were BC patients scheduled to receive systemic treatment (BC + SYST; n = 31), or no systemic treatment (BC; n = 24) and no-cancer (NC) controls (n = 33). Neuropsychological examinations were used to study cognitive performance on 18 tests grouped into eight cognitive domains, before adjuvant treatment (T1) and six months after chemotherapy (T2), or at similar intervals. We also assessed health-related quality of life, anxiety and depression, mood, stress, and cognitive problems. Analysis of variance was used to assess group differences of cognitive performance and multivariate normative comparison to classify impairment, comparing scores of each participant against the distribution of the scores of NC controls. RESULTS: Of BC + SYST, 16% were cognitively impaired at T2, compared to 4% in BC and 6% in NC. Although not significant, we observed moderate effect sizes for worse performance in the BC + SYST group compared to NC (Flanker congruent [effect size {ES} = 0.44] and stimulus incongruent [ES = 0.44]) and compared to BC (Controlled Oral Word Association Test [ES = 0.47], digit span [ES = 0.41], and Hopkins Verbal Learning Test immediate [ES = 0.71] and delayed recall [ES = 0.65]). Cognitively impaired patients had a significantly lower estimated premorbid intelligence, worse physical and social functioning, and more distress at T2 compared to unimpaired patients. CONCLUSION: Our findings indicate that cognitive impairment after systemic treatment occurs in a subset of BC patients. The predictive value of demographic and psychosocial factors in cognitive impairment should be further investigated in a larger sample of impaired patients.


Asunto(s)
Neoplasias de la Mama/psicología , Neoplasias de la Mama/terapia , Disfunción Cognitiva/etiología , Análisis de Varianza , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/epidemiología , Disfunción Cognitiva/epidemiología , Femenino , Humanos , Estudios Longitudinales , Persona de Mediana Edad , Análisis Multivariante , Pruebas Neuropsicológicas , Estudios Prospectivos
3.
J Clin Oncol ; 33(17): 1918-27, 2015 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-25918291

RESUMEN

PURPOSE: We evaluated the effectiveness of a low-intensity, home-based physical activity program (Onco-Move) and a moderate- to high-intensity, combined supervised resistance and aerobic exercise program (OnTrack) versus usual care (UC) in maintaining or enhancing physical fitness, minimizing fatigue, enhancing health-related quality of life, and optimizing chemotherapy completion rates in patients undergoing adjuvant chemotherapy for breast cancer. PATIENTS AND METHODS: We randomly assigned patients who were scheduled to undergo adjuvant chemotherapy (N = 230) to Onco-Move, OnTrack, or UC. Performance-based and self-reported outcomes were assessed before random assignment, at the end of chemotherapy, and at the 6-month follow-up. We used generalized estimating equations to compare the groups over time. RESULTS: Onco-Move and OnTrack resulted in less decline in cardiorespiratory fitness (P < .001), better physical functioning (P ≤ .001), less nausea and vomiting (P = .029 and .031, respectively) and less pain (P = .003 and .011, respectively) compared with UC. OnTrack also resulted in better outcomes for muscle strength (P = .002) and physical fatigue (P < .001). At the 6-month follow-up, most outcomes returned to baseline levels for all three groups. A smaller percentage of participants in OnTrack required chemotherapy dose adjustments than those in the UC or Onco-Move groups (P = .002). Both intervention groups returned earlier (P = .012), as well as for more hours per week (P = .014), to work than the control group. CONCLUSION: A supervised, moderate- to high-intensity, combined resistance and aerobic exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy. A home-based, low-intensity physical activity program represents a viable alternative for women who are unable or unwilling to follow the higher intensity program.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia por Ejercicio , Ejercicio Físico , Fatiga , Actividad Motora , Aptitud Física , Actividades Cotidianas , Adulto , Anciano , Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama/tratamiento farmacológico , Quimioterapia Adyuvante , Esquema de Medicación , Fatiga/prevención & control , Femenino , Estudios de Seguimiento , Estado de Salud , Humanos , Persona de Mediana Edad , Fuerza Muscular , Náusea/inducido químicamente , Náusea/prevención & control , Dolor/etiología , Dolor/prevención & control , Calidad de Vida , Autoinforme , Trastuzumab , Resultado del Tratamiento , Vómitos/inducido químicamente , Vómitos/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA